GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Fresenius SE & Co KGaA (XTER:FRE) » Definitions » Altman Z2-Score

Fresenius SE KGaA (XTER:FRE) Altman Z2-Score : 1.50 (As of May. 21, 2024)


View and export this data going back to 1992. Start your Free Trial

What is Fresenius SE KGaA Altman Z2-Score?

Altman Z2-Score, also known as Z"-Score, is used to predict the likelihood that a non-manufacturing company (excluding property/financial company) will face bankruptcy within a two-year period.

Fresenius SE KGaA has a Altman Z2-Score of 1.50, indicating it is in Grey Zones. This implies that Fresenius SE KGaA is in some kind of financial stress. If it is below 1.1, the company may face bankrupcy risk.

The zones of discrimination were as such:

When Altman Z2-Score <= 1.1, it is in Distress Zones.
When Altman Z2-Score >= 2.6, it is in Safe Zones.
When Altman Z2-Score is between 1.1 and 2.6, it is in Grey Zones.

The historical rank and industry rank for Fresenius SE KGaA's Altman Z2-Score or its related term are showing as below:

XTER:FRE' s Altman Z2-Score Range Over the Past 10 Years
Min: 1.04   Med: 1.33   Max: 1.6
Current: 1.5

During the past 13 years, Fresenius SE KGaA's highest Altman Z2-Score was 1.60. The lowest was 1.04. And the median was 1.33.


Fresenius SE KGaA Altman Z2-Score Historical Data

The historical data trend for Fresenius SE KGaA's Altman Z2-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fresenius SE KGaA Altman Z2-Score Chart

Fresenius SE KGaA Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Altman Z2-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.04 1.14 1.07 1.10 1.50

Fresenius SE KGaA Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Altman Z2-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.10 0.97 0.93 2.01 1.50

Competitive Comparison of Fresenius SE KGaA's Altman Z2-Score

For the Medical Care Facilities subindustry, Fresenius SE KGaA's Altman Z2-Score, along with its competitors' market caps and Altman Z2-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fresenius SE KGaA's Altman Z2-Score Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Fresenius SE KGaA's Altman Z2-Score distribution charts can be found below:

* The bar in red indicates where Fresenius SE KGaA's Altman Z2-Score falls into.



Fresenius SE KGaA Altman Z2-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

Z2-Score, also known as Z"-Score is the Z-Score for non-manufacturing companies excluding property/financial companies.

Fresenius SE KGaA's Altman Z2-Score for today is calculated with this formula:

Z=6.56*X1+3.26*X2+6.72*X3+1.05*X4_2
=6.56*0.0704+3.26*0+6.72*0.0386+1.05*0.7412
=1.50

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z2-Score when X4_2 value is 0.

Trailing Twelve Months (TTM) ended in Dec. 2023:
Total Assets was €45,284 Mil.
Total Current Assets was €12,520 Mil.
Total Current Liabilities was €9,330 Mil.
Retained Earnings was €0 Mil.
Pre-Tax Income was -52 + 246 + 359 + 617 = €1,170 Mil.
Interest Expense was -125 + -100 + -184 + -170 = €-579 Mil.
Total Liabilities was €25,633 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(12520 - 9330)/45284
=0.0704

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(1170 - -579)/45284
=0.0386

X4_2=Net Worth/Total Liabilities
=(Total Stockholders Equity - Preferred Stock)/Total Liabilities
=(18999 - 0)/25633
=0.7412

The zones of discrimination were as such:

Distress Zones - 1.1 < Grey Zones < 2.6 - Safe Zones

Fresenius SE KGaA has a Altman Z2-Score of 1.50 indicating it is in Grey Zones.


Fresenius SE KGaA  (XTER:FRE) Altman Z2-Score Explanation

The original Z-Score model was based on publicly traded manufacturing companies while the Z2-Score, also known as Z"-score can be used for any type of company excluding property/financial companies. Both Z-Score and Z2-Score describes the financial health of a company, and its likelihood of financial distress.

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4_2, Net Worth (Total Stockholders Equity - Preferred Stock)/Total Liabilities (NW/TL): it compares a company’s stock net worth with its total liabilities and can be used to assess the extent of its reliance on debt.

Read more about Altman Z2-Score, the original research on Z-Score and the additional research on Z2-Score.


Be Aware

Altman Z2-Score does not apply to financial companies.


Fresenius SE KGaA Altman Z2-Score Related Terms

Thank you for viewing the detailed overview of Fresenius SE KGaA's Altman Z2-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Fresenius SE KGaA (XTER:FRE) Business Description

Address
Else-Kroener-Strasse 1, Bad Homburg, HE, DEU, 61352
Fresenius SE is a healthcare holding company based in Germany with four segments. The company owns a large stake in dialysis service provider and equipment manufacturer Fresenius Medical Care. The Kabi segment manufactures intravenous drugs, nutrition products, infusion and transfusion therapies, and related pumps. The Helios segment operates private hospitals and fertility clinics in Germany, Spain, and Latin America. Vamed provides a variety of services such as healthcare facility construction and operation management, including post-acute care rehabilitation.
Executives
Dr. Michael Moser Board of Directors
Sara Hennicken Board of Directors
Michael Sen Board of Directors
Dr. Francesco De Meo Board of Directors
Stephan Sturm Board of Directors
Wolfgang Kirsch Supervisory Board
Mats Henriksson Board of Directors
Dr. Gerd Krick Supervisory Board

Fresenius SE KGaA (XTER:FRE) Headlines

No Headlines